1 BTC
=
- USD
Cadrenal Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Market Statistics
Trading Metrics
How to Buy CVKD
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CVKD
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCadrenal Therapeutics announced research findings demonstrating that its first-in-class 12-LOX inhibitor CAD-1005 can reduce inflammation associated with obesity and Type 2 diabetes. Preclinical studies showed CAD-1005 improved glycemic control, reduced pancreatic β-cell loss, and lowered inflammatory markers. The company believes CAD-1005 could complement existing GLP-1 obesity medications. CAD-1005 is currently in clinical development for Heparin-Induced Thrombocytopenia (HIT), with a Phase 2 trial showing reduced thrombotic events.
Cadrenal Therapeutics acquired VLX-1005, a novel small-molecule inhibitor targeting heparin-induced thrombocytopenia (HIT), from Veralox Therapeutics. The drug candidate has shown promising Phase 2 results and received Orphan Drug and Fast Track designations from the FDA.
Kuick Research released a comprehensive study on the US Orphan Drug Market, projecting market opportunities exceeding $190 billion by 2030, with over 850 orphan drugs in clinical trials and 500 marketed orphan drugs, highlighting significant investment potential in rare disease therapeutics.
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 million. Compass Minerals International shares fell 9% to $20.52 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Syra Health Corp. (NASDAQ: SYRA) shares jumped 310% to $4.71 after the company announced a partnership for a federal contract valued at $75 billion. Hitek Global Inc. (NASDAQ: HKIT) surged 305% to $4.6220 after jumping more than 60% on Wednesday. MicroAlgo Inc. (NASDAQ: MLGO) shares climbed 160% to $1.48. CCSC Technology International Holdings Limited (NASDAQ: CCTG) shares gained 90.3% to $4.9299 after falling 20% on Wednesday. U Power Limited (NASDAQ: UCAR) climbed 75% to $0.1153. The company appointed Jean Christophe von Pfetten as an independent director and a member of the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, effective February 1, 2024. WiMi Hologram Cloud Inc. (NASDAQ: WIMI) shares rose 53.3% to $1.2290 after gaining over 26% on Wednesday. Bit Brother Limited (NASDAQ: BETS) shares climbed 51.2% to $2.69 amid strength in Bitcoin. Arm Holdings plc (NASDAQ: ARM) shares climbed 47.3% to $113.41 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates. Zhongchao Inc. (NASDAQ: ZCMD) rose 41.5% to $0.4250. WeTrade Group, Inc. (NASDAQ: WETG) gained 38.6% to $3.05. Meiwu Technology Company Limited (NASDAQ: WNW) jumped 37% to $1.6205. Healthcare Triangle, Inc. (NASDAQ: HCTI) surged 36% to $3.8250. Oscar Health, Inc. (NYSE: OSCR) shares rose 21.2% to $16.27 after the company reported better-than-expected fourth-quarter financial results. Roma Green Finance Limited (NASDAQ: ROMA) shares gained 20.4% to $0.94 after declining over 5% on Wednesday. Mineralys Therapeutics, Inc. (NASDAQ: MLYS) surged 18.5% to $14.77. Mineralys Therapeutics announced ...
